查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493176

免疫查核點抑制劑市場規模、佔有率、趨勢分析報告：按類型、應用、分銷管道、地區、細分市場預測，2024-2030

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1, PD-L1, CTLA-4), By Application (Lung Cancer, Breast Cancer, Melanoma), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

免疫查核點抑制劑市場成長與趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球免疫查核點抑制劑市場規模預計將達到1,542.5億美元，2024年至2030年複合年成長率為17.9%。

癌症盛行率的增加以及 FDA 對免疫查核點抑制劑的核准增加推動了市場的成長。此外，增加資金以推動癌症免疫治療，加上研究機構和主要參與者不斷增加的研發活動，進一步推動了市場成長。

多種癌症盛行率的上升以及對適當治療方案的需求不斷成長預計將推動市場成長。例如，根據國際癌症研究機構 (IARC) 的數據，預計 2023 年將出現超過 2,070 萬名新癌症患者。此外，根據乳癌統計和資源的數據，2020 年全球約有 230 萬名女性被診斷出罹患乳癌。此外，醫療保健專業人員和患者對化療和放射線治療副作用的認知不斷提高，是影響免疫查核點抑制劑等替代療法成長的主要因素。

癌症免疫治療資金的增加預計將在不久的將來為市場提供利潤豐厚的機會。各國政府和主要機構不斷致力於透過鼓勵研究和開發活動來醫療費用支出，其中包括免疫查核點抑制劑。例如，2023 年 7 月，癌症研究所津貼約 2,800 萬美元，以促進免疫療法的創新。同樣，2021 年 7 月，蘭金政府宣布投資 1,800 萬美元，用於改善癌症治療，包括免疫查核點抑制劑。諸如此類的措施正在推動市場成長。

然而，免疫查核點抑制劑在癌症治療中的高相關成本和併發症帶來了重大挑戰。用於癌症治療的免疫查核點抑制劑可能會引起免疫相關的不利事件。這些併發症包括皮膚問題、胃腸道疾病（如結腸炎）、內分泌功能障礙、肺炎、風濕病、神經和心臟併發症以及腎臟問題。 ICI 對癌症顯示出強大的功效，預計這些副作用將阻礙預測期內的市場成長。

免疫查核點抑制劑市場報告亮點

  • 按產品類型分類，由於研發活動活性化、產品核可增加以及Pembrolizumab和納武單抗等藥物處方的快速增加，PD-1細分市場在2023年以73.3%的最大銷售佔有率引領市場。
  • 從應用來看，肺癌領域佔市場最大，2023年銷售量為25.41%。肺癌患者數量的增加是推動該細分市場成長的關鍵因素。
  • 從應用來看，大腸直腸癌領域預計在預測期內將以最快的複合年成長率成長。
  • 按分銷管道分類，由於藥品採購的可及性和便利性提高，預計線上藥局領域在預測期內將以最快的複合年成長率成長。
  • 由於癌症盛行率上升、購買力平價高、政府對優質醫療保健的支持以及可報銷等因素，北美在 2023 年以 62.81% 的銷售佔有率佔據市場主導地位。
  • 2023年3月，BioNTech與OncoC4建立策略聯盟，開始共同開發和商業化適用於多種固體癌的新型免疫檢查查核點抑制劑抗CTLA-4單株抗體候選藥物。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章免疫查核點抑制劑市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 免疫查核點抑制劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 管道分析

第4章 免疫查核點抑制劑市場：類型估計與趨勢分析

  • 全球免疫查核點抑制劑市場：類型儀表板
  • 全球免疫查核點抑制劑市場：類型變異分析
  • 按類型分類的收益
  • PD-1
  • PD-L1
  • CTLA-4
  • 其他

第5章 免疫查核點抑制劑市場：應用預估及趨勢分析

  • 全球免疫查核點抑制劑市場：應用儀表板
  • 全球免疫查核點抑制劑市場：應用變化分析
  • 按使用情況分類的收益
  • 肺癌
  • 乳癌
  • 膀胱癌
  • 惡性黑色素瘤
  • 子宮頸癌
  • 何傑金氏淋巴瘤
  • 大腸直腸癌
  • 其他

第6章 免疫查核點抑制劑市場：通路估算及趨勢分析

  • 全球免疫查核點抑制劑市場：分銷通路儀表板
  • 全球免疫查核點抑制劑市場：通路波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章免疫查核點抑制劑市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030 年市場規模、預測與分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Shanghai Jhunsi Biosciences Ltd
    • Immutep Ltd
    • BeiGene Ltd
    • GlaxoSmithKline PLC
Product Code: GVR-4-68040-257-4

Immune Checkpoint Inhibitors Market Growth & Trends:

The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.

The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.

Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.

However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.

Immune Checkpoint Inhibitors Market Report Highlights:

  • Based on type, the PD-1 segment led the market with the largest revenue share of 73.3% in 2023, owing to growing R&D activities, increasing product approvals and surge in prescription of drugs such as pembrolizumab and nivolumab
  • Based on application, the lung cancer segment held the market with the largest revenue share of 25.41% in 2023. Increase in number of lung cancer cases is a significant factor driving growth of this segment
  • Based on application, the colorectal cancer segment is expected to grow at the fastest CAGR over forecast period
  • Based on the distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing accessibility and convenience of drug procurement
  • North America dominated the market with the revenue share of 62.81% in 2023, owing to factors such as increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
  • In March 2023, BioNTech, entered into strategic collaboration with OncoC4 to co-develop and commercialize new immune checkpoint inhibitor anti-CTLA-4 monoclonal antibody candidate for multiple solid tumor indications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in Asia Pacific
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Immune Checkpoint Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Increasing R&D investments
      • 3.2.1.3. Rise in healthcare spending
      • 3.2.1.4. New product approvals and launches
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of immune checkpoint inhibitors
  • 3.3. Immune Checkpoint Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis

Chapter 4. Immune Checkpoint Inhibitors Market: Type Estimates & Trend Analysis

  • 4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
  • 4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
  • 4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
  • 4.4. PD-1
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PD-L1
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. CTLA-4
    • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Immune Checkpoint Inhibitors Market: Application Estimates & Trend Analysis

  • 5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
  • 5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
  • 5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
  • 5.4. Lung Cancer
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Breast Cancer
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Bladder Cancer
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Melanoma
    • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Cervical Cancer
    • 5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Hodgkin Lymphoma Cancer
    • 5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. Colorectal Cancer
    • 5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Immune Checkpoint Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Immune Checkpoint Inhibitors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Sanofi
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bristol-Myers Squibb Company
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Eli Lilly and Company
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Regeneron Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca PLC
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Shanghai Jhunsi Biosciences Ltd
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Immutep Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. BeiGene Ltd
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. GlaxoSmithKline PLC
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Germany immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 20 U.K. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 21 U.K. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 23 France immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 24 France immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 China immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 45 China immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 46 China immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Japan immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 48 Japan immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 51 India immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 52 India immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 54 South Korea immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 57 Australia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 60 Thailand immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 63 Latin America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Brazil immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 66 Brazil immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 67 Brazil immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 Mexico immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 69 Mexico immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 70 Mexico immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Argentina immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 MEA immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 76 MEA immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 South Africa immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 79 South Africa immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 UAE immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 85 UAE immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Kuwait immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 88 Kuwait immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in APAC
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Immune checkpoint inhibitors market: market outlook
  • Fig. 10 Immune checkpoint inhibitors competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Immune checkpoint inhibitors market driver impact
  • Fig. 16 Immune checkpoint inhibitors market restraint impact
  • Fig. 17 Immune checkpoint inhibitors market strategic initiatives analysis
  • Fig. 18 Immune checkpoint inhibitors market: Type movement analysis
  • Fig. 19 Immune checkpoint inhibitors market: Type outlook and key takeaways
  • Fig. 20 PD-1 market estimates and forecast, 2018 - 2030
  • Fig. 21 PD-L1 estimates and forecast, 2018 - 2030
  • Fig. 22 CTLA-4 market estimates and forecast, 2018 - 2030
  • Fig. 23 Others estimates and forecast, 2018 - 2030
  • Fig. 24 Immune checkpoint inhibitors market: Application movement analysis
  • Fig. 25 Immune checkpoint inhibitors market: Application outlook and key takeaways
  • Fig. 26 Lung cancer market estimates and forecasts, 2018 - 2030
  • Fig. 27 Breast cancer market estimates and forecasts,2018 - 2030
  • Fig. 28 Bladder cancer market estimates and forecasts,2018 - 2030
  • Fig. 29 Melanoma market estimates and forecasts, 2018 - 2030
  • Fig. 30 Cervical cancer market estimates and forecasts,2018 - 2030
  • Fig. 31 Hodgkin lymphoma market estimates and forecasts,2018 - 2030
  • Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
  • Fig. 33 Others market estimates and forecasts,2018 - 2030
  • Fig. 34 Immune checkpoint inhibitors market: Distribution channel movement analysis
  • Fig. 35 Immune checkpoint inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 37 Retail pharmacies market estimates and forecasts,2018 - 2030
  • Fig. 38 Online pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global immune checkpoint inhibitors market: Regional movement analysis
  • Fig. 40 Global immune checkpoint inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global immune checkpoint inhibitors market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 US market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 54 France market estimates and forecasts, 2018 - 2030
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 China market estimates and forecasts, 2018 - 2030
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 India market estimates and forecasts, 2018 - 2030
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 74 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 76 Market share of key market players - Immune checkpoint inhibitors market